Q&A: BIO CEO Michelle McMurry-Heath Outlines Diversity Goals

New BIOEquality Agenda Tackles Trial Participation, Access, Education

Expanding on difficult conversations during the recent BIO Digital meeting, the group aims to take actions that will increase diversity and inclusion in health care, science and industry.

Designer Teamwork Brainstorming Planning Meeting Concept — The BIOEquality Agenda is focused on clinical trials, health care and the workforce • Source: Shutterstock

It would be hard to find a more challenging time for Michelle McMurry-Heath to join the Biotechnology Innovation Organization as its CEO given the COVID-19 pandemic and the protests over racial inequality in the US. But the organization is trying to rise to the occasion on both fronts, with biotech companies pioneering new responses to the pandemic and a new push on diversity and inclusion.

BIO recently unveiled its BIOEquality Agenda, which outlines goals for reducing systemic inequality, injustice and unfair treatment of women and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.